Loxo Lays Out Plans For BTK Inhibitor LOXO-305 In CLL

Data At ASH Show Strong Post-Imbruvica Efficacy

 
• By Alaric DeArment

The company said investigators had been choosing the drug over Venclexta due to its less cumbersome administration, especially amid the COVID-19 pandemic.

Leukemia cell (blast cell)
Loxo Oncology at Lilly announced Phase I/II data for its BTK inhibitor in CLL • Source: Shutterstock

More from Strategy

More from Business